Advertisement

Pharmaceutical Chemistry Journal

, Volume 53, Issue 1, pp 23–28 | Cite as

Synthesis and Antiarrhythmic Activity of N-[2-(Adamantan-2-YL)Aminocarbonyl-Methyl-N′-(Dialkylamino)Alkylnitrobenzamides

  • N. I. AvdyuninaEmail author
  • A. I. Turilova
  • T. S. Gan’shina
  • R. S. Mirzoyan
  • L. N. Grushevskaya
  • N. M. Zaitseva
  • B. M. Pyatin
Article
  • 19 Downloads

Novel 2-aminoadamantane derivatives, specifically N-[2-(adamant-2-yl)-aminocarbonylmethyl]-N′-(dialkylamino) alkylnitrobenzamides and their physiologically compatible salts, preferably the hydrochlorides, were synthesized and their pharmacological properties were studied. The novel derivatives were found to have marked antiarrhythmic (antifibrillatory) activity in models of calcium chloride and aconitin arrhythmia. The relationship between the chemical structures of the substances synthesized here and their pharmacological activities was studied. The highest level of antiarrhythmic activity and the lowest toxicity were obtained with compound N-[2-(adamant-2-yl)aminocarbonylmethyl]-N′-[3-diethylamino]propyl]-4-nitrobenzamide, which also had the advantage of a wider therapeutic ratio over known antiarrhythmic drugs of classes I, IV, and III (cardiocyclide).

References

  1. 1.
    A. V. Nedostup, O. V. Blagova, Rus. Med. Zh., 13(11), 767 – 774 (2005).Google Scholar
  2. 2.
    A. V. Nedostup, Kardiologiya, 16(6), 431 – 435 (2008).Google Scholar
  3. 3.
    M. D. Mashkovskii, Medicines [in Russian], Moscow, Novaya Volna (2000).Google Scholar
  4. 4.
    M. D. Mashkovskii, R. G. Glushkov, E. V. Dorodnikova, and S. D. Yuzhakov, Khim.-Farm. Zh., 29(3), 27 – 31 (1995).Google Scholar
  5. 5.
    R. G. Glushkov, S. P. Golitsin, E. V. Dorodnikova, et al., Vest. RAMN, 11, 38 – 42 (1998).Google Scholar
  6. 6.
    C. E. Pollard, Gerges Abi, M. H. Bridgland-Taylor, et al., Br. J. Pharmacol., 159(1), 12 – 21 (2010).CrossRefGoogle Scholar
  7. 7.
    I. Savelieva, J. Camm. Europace, 10(6), 646 – 665 (2008).Google Scholar
  8. 8.
    H. Wulf, N. A. Castle, L. A. Pardo, et al., Rev. Drug Discov., 8(12), 982 – 1001 (2009).CrossRefGoogle Scholar
  9. 9.
    H. Poppl, R. Schindler, W. Sauer, et al., Arch. Pharm. Med. Chem., 332(7), 223 – 241 (1999).Google Scholar
  10. 10.
    V. Zauer, R. Shindlur, K. Ryuger, et al., Russian Federation Patent No. 2134683, Byul. Izobret., No. 23 (1999).Google Scholar
  11. 11.
    P. A. Galenko-Yaroshevskii, N. V. Kaverina, A. G. Kamkin, et al., Guidelines for Preclinical Studies of Drugs [in Russian], Grif i K, Moscow (2012), part 1, pp. 385 – 387.Google Scholar
  12. 12.
    N. V. Kaverina, V. V. Lyskovtsev, S. F. Sokolov, et al., Vestnik RAMN, No. 11, 42 – 46 (1998).Google Scholar
  13. 13.
    I. E. Kovalev, Khim.-Farm. Zh., 11(3), 19 – 27 (1977).Google Scholar
  14. 14.
    S. N. Pandeya, Indian J. Pharm., 33, 1 (1971).Google Scholar
  15. 15.
    L. N. Lavrova, N. V. Klimova, M. I. Shmar’yan, et al., Zh. Organ. Khimii, VIII, 2445 – 2446 (1972).Google Scholar
  16. 16.
    N. I. Avdyunina, I. S. Morozov, B. M. Pyatin, et al., Khim.-Farm. Zh., 22(7), 819 – 822 (1988); Pharm. Chem. J., 22(7), 543 – 546 (1988).Google Scholar
  17. 17.
    I. G. Ninidze, A. I. Turilova, S. Yu. Berdyaev, et al., The New Antiarrhythmic Drug Bonnecor. Collected Papers [in Russian], N. V. Kaverina and G. G. Chichkanova (eds.), Moscow (1993), pp. 124 – 127.Google Scholar
  18. 18.
    A. I. Turilova, S. Yu. Berdyaev, A. N. Gritsenko, Z. P. Senova, Farmakol. Toksikol., No. 6, 20 – 21, No. 1990).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • N. I. Avdyunina
    • 1
    Email author
  • A. I. Turilova
    • 1
  • T. S. Gan’shina
    • 1
  • R. S. Mirzoyan
    • 1
  • L. N. Grushevskaya
    • 1
  • N. M. Zaitseva
    • 1
  • B. M. Pyatin
    • 1
  1. 1.V. V. Zakusov Science Research Institute of PharmacologyMoscowRussia

Personalised recommendations